신경병증성 통증 치료제 파이프라인 분석(2026년)(2분기 인사이트와 임상시험)

Neuropathic pain results from injury or dysfunction of the somatosensory nervous system and remains one of the most challenging chronic pain conditions to treat. Current therapies, including gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, topical agents, and selected opioids, frequently provide incomplete symptom relief and are associated with tolerability limitations. Consequently, pharmaceutical developers are increasingly focusing on mechanism-specific therapies that selectively target the biological pathways responsible for chronic pain generation rather than providing generalized analgesia.

Market Drivers

Growing Burden of Neuropathic Disorders

Increasing global prevalence of diabetes, cancer survivorship, chemotherapy-related neuropathy, spinal disorders, and neurodegenerative diseases continues expanding the addressable patient population and driving demand for innovative therapies.

Demand for Non-Opioid Therapeutics

Growing concern regarding opioid dependence and long-term safety is accelerating pharmaceutical investment in highly selective non-opioid therapies capable of providing sustained pain relief while minimizing central nervous system adverse effects.

Advances in Molecular Neuroscience

Improved understanding of ion channels, neuroimmune signaling, inflammatory mediators, and neuronal regeneration has enabled the identification of numerous validated therapeutic targets that support first-in-class drug development.

Precision Medicine

Biomarker-guided patient selection, genetic profiling, and translational neuroscience are improving clinical trial design, increasing development efficiency, and supporting personalized treatment strategies.

Market Restraints

High Clinical Development Risk

Neuropathic pain studies often experience significant placebo responses, heterogeneous patient populations, and variable clinical outcomes, increasing development uncertainty and costs.

Disease Complexity

Multiple disease mechanisms contribute to neuropathic pain, making universal treatment approaches difficult and requiring highly targeted therapeutic strategies.

Stringent Regulatory Expectations

Regulatory authorities increasingly require durable efficacy, long-term safety, clinically meaningful pain reduction, and robust patient-reported outcomes before approving innovative therapies.

Pipeline and Technology Insights

The global neuropathic pain drug pipeline can be segmented by clinical development phase, mechanism of action, drug modality, target indication, molecule type, sponsor type, regulatory status, and geography.

By clinical development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review programs. Most pipeline activity remains concentrated in early-stage development as companies validate novel biological targets before progressing into pivotal studies. Phase II programs represent one of the most active stages of clinical development.

By mechanism of action, investigational therapies target selective sodium channel modulators, calcium channel modulators, TRP channel modulators, NMDA receptor modulators, cannabinoid-based therapies, neuroimmune modulators, neurotrophic approaches, inflammatory signaling pathways, and other emerging biological targets. Selective sodium channel inhibition remains one of the most active areas of innovation because of its potential to provide effective analgesia with reduced systemic adverse effects.

By drug modality, the pipeline includes small molecules, biologics, monoclonal antibodies, RNA therapeutics, gene therapies, cell therapies, and regenerative medicine platforms. Small molecules continue to dominate development because of oral administration, established manufacturing capabilities, and well-defined regulatory pathways, while advanced biologics and genetic therapies represent emerging areas of innovation.

By target indication, pipeline development addresses diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, small fiber neuropathy, radiculopathy, central neuropathic pain, and other neuropathic pain disorders. Diabetic peripheral neuropathy remains the largest commercial opportunity because of its growing global prevalence.

Pipeline Trends

The neuropathic pain drug pipeline continues evolving through scientific innovation.

Key trends include:

• Expansion of selective sodium channel inhibitor development.
• Increasing investment in non-opioid therapeutics.
• Growth of RNA therapeutics and gene therapy programs.
• Greater adoption of biomarker-guided clinical development.
• Increased application of artificial intelligence in drug discovery.
• Expansion of precision medicine strategies.
• Stronger licensing agreements and biotechnology partnerships.

Regional Insights

North America remains the leading region for neuropathic pain drug development because of advanced neuroscience research infrastructure, strong biotechnology investment, supportive regulatory pathways, and extensive clinical trial activity. The United States hosts many of the world's leading pharmaceutical and biotechnology companies developing next-generation pain therapeutics.

Europe continues to maintain strong pipeline activity through collaborative neuroscience research, standardized clinical development frameworks, and active academic-industry partnerships supporting innovation across multiple therapeutic modalities.

Asia-Pacific is rapidly emerging as an important development region owing to increasing diabetes prevalence, expanding pharmaceutical research capabilities, improving healthcare infrastructure, and greater investment in translational neuroscience. China, Japan, South Korea, Australia, and India continue attracting multinational clinical development programs.

Latin America and the Middle East & Africa continue strengthening participation in multinational development programs as healthcare infrastructure, regulatory systems, and neurological disease management continue improving.

Pipeline Landscape

The current neuropathic pain pipeline demonstrates substantial scientific diversification compared with previous decades. Companies are moving beyond conventional analgesics toward therapies targeting validated molecular mechanisms such as sodium channels, neuroimmune pathways, kinase signaling, inflammatory mediators, and neuronal regeneration. Recent industry developments include Sangamo Therapeutics receiving FDA Fast Track designation for ST-503 for small fiber neuropathy, Toray Industries licensing TRK-750 to Sanodyne Therapeutics, and MIRA Pharmaceuticals initiating Phase I development of Ketamir-2 for neuropathic pain.

Future Outlook

The future neuropathic pain drug pipeline will increasingly emphasize personalized medicine, biomarker-driven development, selective ion-channel pharmacology, regenerative medicine, RNA therapeutics, and artificial intelligence-assisted drug discovery. Continued advances in molecular neuroscience are expected to improve target validation, reduce clinical development risk, and accelerate commercialization of innovative non-opioid therapies through 2035.

Conclusion

The Global Neuropathic Pain Drug Pipeline Analysis demonstrates a rapidly evolving innovation landscape supported by growing disease prevalence, expanding scientific understanding, and increasing demand for safer non-opioid pain therapies. Although placebo response, disease heterogeneity, and stringent regulatory expectations remain significant challenges, continued advances in mechanism-based drug development, precision medicine, and translational neuroscience are expected to create substantial opportunities for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global neuropathic pain drug pipeline.
• Detailed evaluation of investigational therapies across all stages of development.
• Analysis of mechanisms of action, therapeutic modalities, and innovation trends.
• Competitive intelligence covering pipeline assets, licensing activity, regulatory developments, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, consultants, and investors.

What Businesses Use Our Reports For

Pipeline benchmarking, portfolio prioritization, clinical development planning, licensing evaluation, partnership identification, competitive intelligence, investment analysis, commercialization strategy, regulatory planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global neuropathic pain drug pipeline by clinical development phase, mechanism of action, drug modality, target indication, molecule type, sponsor type, regulatory status, and geography
• Evaluation of pipeline assets, clinical development progress, regulatory milestones, commercialization opportunities, competitive positioning, and innovation trends
• Assessment of precision medicine strategies, biomarker-guided development, artificial intelligence integration, licensing activities, strategic collaborations, and future therapeutic opportunities
• Analysis of selective sodium channel modulators, calcium channel modulators, TRP channel modulators, NMDA receptor modulators, cannabinoid-based therapies, neuroimmune modulators, neurotrophic approaches, small molecules, biologics, RNA therapeutics, gene therapies, cell therapies, regenerative medicine platforms, and emerging neuropathic pain drug candidates through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Global Neuropathic Pain Therapeutic Area Snapshot
  • 1.1.1 Epidemiology burden and diagnosis gaps
  • 1.1.2 Treatment landscape limitations (first-line, second-line, refractory cases)
  • 1.1.3 Unmet need intensity across diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, and central neuropathic pain
  • 1.1.4 Pipeline maturity overview (early-stage vs late-stage balance)
  • 1.1.5 Key innovation inflection points in analgesic R&D
• 1.2 Key Pipeline Intelligence Findings (Registry-Verified Framework Only)
  • 1.2.1 Total active investigational assets (to be confirmed via ClinicalTrials.gov/EUCTR/company filings)
  • 1.2.2 Phase distribution summary (Preclinical-Phase III)
  • 1.2.3 Dominant mechanisms under investigation
  • 1.2.4 Attrition hotspots across historical neuropathic pain programs
  • 1.2.5 Emerging high-probability development clusters

2. Pipeline Overview

• 2.1 Global Neuropathic Pain Drug Development Landscape
  • 2.1.1 Total pipeline assets (registry-confirmed only)
  • 2.1.2 Asset distribution across development stages
  • 2.1.3 Small molecule vs biologics vs emerging modalities split
  • 2.1.4 Indication-wise segmentation (diabetic, post-herpetic, trigeminal neuralgia, chemotherapy-induced, others)
• 2.2 Pipeline Evolution Dynamics
  • 2.2.1 Historical transition rates from Phase I to approval
  • 2.2.2 Discontinuation trends in analgesic development
  • 2.2.3 Shift from opioid-centric to non-opioid mechanisms
  • 2.2.4 Increasing role of ion-channel modulation strategies

3. Disease & Unmet Need Analysis

• 3.1 Neuropathic Pain Pathophysiology Overview
  • 3.1.1 Peripheral vs central sensitization mechanisms
  • 3.1.2 Role of sodium, calcium, and TRP channels
  • 3.1.3 Neuroinflammation and glial activation pathways
• 3.2 Treatment Gaps
  • 3.2.1 Inadequate responder rates in first-line therapies
  • 3.2.2 Safety/tolerability constraints of current standard-of-care
  • 3.2.3 Chronicity and relapse burden
  • 3.2.4 Limited disease-modifying therapies

4. Mechanism & Modality Landscape

• 4.1 Mechanism of Action (MoA) Clustering Framework
  • 4.1.1 Voltage-gated sodium channel inhibitors (Nav1.7, Nav1.8 targeting strategies)
  • 4.1.2 Calcium channel modulation approaches
  • 4.1.3 GABAergic and glutamatergic modulation strategies
  • 4.1.4 TRP channel antagonism (TRPV1/TRPA1)
  • 4.1.5 Neuroinflammation and cytokine-targeting mechanisms
  • 4.1.6 Gene regulation and RNA-based modulation (emerging)
• 4.2 Modality Segmentation
  • 4.2.1 Small molecules (dominant modality in current pipeline)
  • 4.2.2 Biologics (monoclonal antibodies, peptide-based agents)
  • 4.2.3 RNA therapeutics (siRNA/antisense exploratory programs)
  • 4.2.4 Cell and gene therapy exploration (early-stage research only)
• 4.3 Innovation Classification
  • 4.3.1 First-in-class mechanisms (novel ion-channel and neuroimmune targets)
  • 4.3.2 Best-in-class optimization strategies
  • 4.3.3 Reformulations of existing analgesic classes

5. Clinical Development Intelligence

• 5.1 Trial Design Benchmarking
  • 5.1.1 Sample size distribution across neuropathic pain trials
  • 5.1.2 Primary endpoint selection trends (pain score scales, responder rates)
  • 5.1.3 Trial duration and follow-up variability
  • 5.1.4 Placebo response inflation patterns
• 5.2 Clinical Success & Failure Analysis
  • 5.2.1 Phase II attrition drivers in analgesic programs
  • 5.2.2 Phase III failure determinants (efficacy vs safety imbalance)
  • 5.2.3 Recruitment bottlenecks in chronic pain populations
  • 5.2.4 Geographic variability in patient enrollment efficiency
• 5.3 Registry-Verified Trial Mapping Framework
  • 5.3.1 ClinicalTrials.gov-registered neuropathic pain studies
  • 5.3.2 EU Clinical Trials Register-verified programs
  • 5.3.3 Sponsor-reported clinical updates (company filings only)

6. Pipeline Segmentation (by Phase, MoA, Modality)

• 6.1 Preclinical Pipeline
  • 6.1.1 Mechanism-classified preclinical assets (registry/company disclosed only)
  • 6.1.2 Early translational biomarkers and target validation programs
• 6.2 Phase I Pipeline
  • 6.2.1 Safety/tolerability-focused first-in-human programs
  • 6.2.2 MoA distribution in early clinical testing
  • 6.2.3 Pharmacokinetic optimization strategies
• 6.3 Phase II Pipeline
  • 6.3.1 Proof-of-concept efficacy studies
  • 6.3.2 Dose-ranging and responder enrichment strategies
  • 6.3.3 Mid-stage attrition risk concentration
• 6.4 Phase III Pipeline
  • 6.4.1 Late-stage confirmatory trials
  • 6.4.2 Regulatory endpoint alignment strategies
  • 6.4.3 Commercial positioning prior to approval
• 6.5 Filed / Under Regulatory Review
  • 6.5.1 Regulatory submissions (FDA/EMA/PMDA where applicable)
  • 6.5.2 Label expansion strategies for neuropathic indications

7. Probability of Success & Risk Analysis

• 7.1 Phase Transition Probability Model
  • 7.1.1 Preclinical ? Phase I success probability ranges
  • 7.1.2 Phase I ? Phase II conversion benchmarks
  • 7.1.3 Phase II ? Phase III historical success rates in neuropathic pain
  • 7.1.4 Phase III ? Approval likelihood modeling
• 7.2 Attrition Risk Mapping
  • 7.2.1 Efficacy failure risk drivers
  • 7.2.2 Safety and tolerability constraints
  • 7.2.3 Placebo-adjusted signal dilution risks
• 7.3 Risk-Adjusted Pipeline Valuation
  • 7.3.1 Probability-weighted asset valuation framework
  • 7.3.2 Scenario-based forecasting (base/bull/bear cases)

8. Launch Timeline & Commercial Potential

• 8.1 Expected Approval Timeline Distribution
  • 8.1.1 Near-term launches (0-3 years)
  • 8.1.2 Mid-term launches (3-7 years)
  • 8.1.3 Long-term pipeline maturation (>7 years)
• 8.2 Commercial Opportunity Mapping
  • 8.2.1 Peak sales potential by mechanism class
  • 8.2.2 Competitive entry timing impact
  • 8.2.3 Pricing sensitivity in chronic pain markets

9. Competitive Pipeline Landscape

• 9.1 Company-Level Pipeline Strength
  • 9.1.1 Large pharma neuropathic pain portfolios
  • 9.1.2 Mid-sized specialty neuroscience players
  • 9.1.3 Biotech innovators with first-in-class assets
• 9.2 Competitive Positioning
  • 9.2.1 Leader vs challenger segmentation
  • 9.2.2 MoA concentration vs diversification strategies
  • 9.2.3 Pipeline redundancy and differentiation gaps

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Clinical trial density and sponsor concentration
  • 10.1.2 Regulatory efficiency and approval timelines
• 10.2 Europe
  • 10.2.1 EU clinical trial network participation
  • 10.2.2 Regulatory harmonization impact
• 10.3 Asia-Pacific
  • 10.3.1 Rising clinical trial outsourcing activity
  • 10.3.2 Innovation hubs and CRO expansion
• 10.4 Latin America
  • 10.4.1 Emerging recruitment advantages
  • 10.4.2 Regulatory variability
• 10.5 Middle East & Africa
  • 10.5.1 Early-stage trial participation trends
  • 10.5.2 Infrastructure constraints and opportunities

11. Key Countries Analysis (Separate Section)

• 11.1 United States - Trial leadership and FDA-driven development standards
• 11.2 Canada - Early-phase trial participation and academic research strength
• 11.3 Germany - EU clinical excellence hub
• 11.4 United Kingdom - translational neuroscience leadership
• 11.5 France - regulatory alignment and hospital network trials
• 11.6 Italy - specialist pain research centers
• 11.7 Spain - chronic pain clinical recruitment strength
• 11.8 China - expanding domestic analgesic innovation pipeline
• 11.9 Japan - regulatory rigor and late-stage trial focus
• 11.10 India - cost-efficient clinical trial execution base
• 11.11 South Korea - biotech-driven neurology innovation
• 11.12 Australia - early-phase safety trial hub
• 11.13 Brazil - Latin American recruitment hub
• 11.14 Mexico - cross-border clinical trial participation
• 11.15 Saudi Arabia - emerging clinical research infrastructure
• 11.16 South Africa - regional trial participation and infectious-comorbidity overlap considerations

12. Deals & Investment Landscape

• 12.1 Licensing Agreements in Neuropathic Pain Therapeutics
• 12.2 Co-development and risk-sharing models
• 12.3 M&A activity involving CNS pain assets
• 12.4 Venture capital funding trends in pain-focused biotech
• 12.5 Strategic partnerships with CROs and academic institutions

13. Future Outlook & Strategic Insights

• 13.1 Shift toward non-opioid analgesic innovation
• 13.2 Precision medicine approaches in pain stratification
• 13.3 Biomarker-driven trial enrichment strategies
• 13.4 Expansion of digital pain monitoring endpoints
• 13.5 Long-term disease-modifying therapy potential

14. Methodology & Data Framework

• 14.1 Data Sources
  • 14.1.1 ClinicalTrials.gov registry extraction framework
  • 14.1.2 EU Clinical Trials Register integration approach
  • 14.1.3 Company pipeline disclosure validation rules
• 14.2 Inclusion / Exclusion Criteria
  • 14.2.1 Neuropathic pain indication eligibility rules
  • 14.2.2 Registry verification thresholds
  • 14.2.3 Exclusion of unverified or speculative assets
• 14.3 Analytical Framework
  • 14.3.1 Phase classification methodology
  • 14.3.2 MoA standardization taxonomy
  • 14.3.3 Probability modeling assumptions
  • 14.3.4 Commercial forecasting methodology
• 14.4 Limitations
  • 14.4.1 Public registry completeness constraints
  • 14.4.2 Disclosure lag in early-stage pipelines
  • 14.4.3 Variability in endpoint definitions across trials